VANLENT ANNE 4
4 · Trevi Therapeutics, Inc. · Filed Jun 4, 2026
Research Summary
AI-generated summary of this filing
Trevi Therapeutics (TRVI) Director Anne Vanlent Receives Option Award
What Happened Anne Vanlent, a director of Trevi Therapeutics (TRVI), was granted an option award for 35,000 shares on June 3, 2026. The Form 4 reports the acquisition as a derivative award with a reported acquisition price of $0.00 (total reported value $0). This is an award (grant), not a purchase or sale of shares.
Key Details
- Transaction date: June 3, 2026; filing date: June 4, 2026 (filed timely).
- Instrument: Option grant for 35,000 shares; reported acquisition price $0.00 (derivative).
- Vesting: Scheduled to fully vest on the earlier of (i) the first anniversary of the grant date or (ii) the date of the next annual meeting of stockholders, subject to continued service (per footnote).
- Shares owned after transaction: Not specified in this filing.
- No indication of a 10b5-1 plan, tax-withholding sale, or late filing in this record.
Context This is a typical director equity grant used for compensation and retention. As an award (not a cash purchase), it does not directly signal a buy/sell decision by the insider and may vest over time based on continued service.
Insider Transaction Report
Form 4
VANLENT ANNE
Director
Transactions
- Award
Nonstatutory Stock Option (right to buy)
[F1]2026-06-03+35,000→ 35,000 totalExercise: $13.45Exp: 2036-06-02→ Common Stock (35,000 underlying)
Footnotes (1)
- [F1]This option was granted on June 3, 2026. This option is scheduled to fully vest on the earlier of (i) the first anniversary of the date of grant and (ii) the date of the next annual meeting of stockholders of the Issuer held following the date of grant, subject to the recipient's continued service as a director, employee or consultant of the Issuer.
Signature
/s/ Christopher Galletta, attorney-in-fact|2026-06-04